Strategies and new developments in the generation of patient-specific pluripotent stem cells.

By S. Yamanaka. Cell Stem Cell, 2007

763 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/4f9de9b643842ca1d41ccb6084e42f8e3858e594

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Physiology

Citations in the corpus

Biomaterial technology for tissue engineering applications (2009, background): “Embryonic stem (ES; Mountford 2008) and inducible pluripotent stem (iPS) cells (Yamanaka 2007) have been established and expected as cell sources for transplantationtherapyandthe researchanddevelopment of drugs.”
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. (2007, background): “We speculate that c-Myc and Klf4 modifies chromatin structure so that Oct3/4 and Sox2 can bind to their targets (Yamanaka, 2007).”
Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon (2009, neutral): “Reprogramming of differentiated somatic cells into a pluripotent state has been carried out by cell fusion or nuclear transfer 1.”
Pluripotency: Toward a gold standard for human ES and iPS cells (2009, background): “IPS technology holds enormous promise as it raises the prospect of derivation of disease-specific (Dimos et al., 2008; Park et al., 2008) and, potentially, patient-specific pluripotent cells (Yamanaka, 2007).”
Induction of pluripotent stem cells from fibroblast cultures (2007, background): “One way to circumvent these issues is to generate pluripotent cells directly from somatic cell”
c-Myc is dispensable for direct reprogramming of mouse fibroblasts. (2008, background): “The promise of somatic reprogramming is the possibility to generate pluripotent stem cells that are patient specific and can be used as a unique source for autologous cell types for transplantation therapy (Jaenisch, 2004; Yamanaka, 2007).”
Mammalian Krüppel-Like Factors in Health and Diseases (2010, background): “6), KLF4 and c-Myc may cooperate to promote iPS cell self-renewal, with KLF4 suppressing apoptosis induced by c-Myc and c-Myc neutralizing the cytostatic effect of KLF4 by suppressing p21 (470).”
Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells (2007, background): “For example, high c-myc/Klf4 and insufficient Oct4/Sox2 expression may lead to rapidly growing non-iPS cells, consistent with the notion that the role of Oct4 and Sox2 in the reprogramming process may be suppression of the c-myc- and Klf4-transformed phenotyp”
Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. (2008, background): “In addition, the reprogramming of adult cells into embryonic stem (ES) cells enables the generation of patient-specific stem cells and thus has enormous potential for the treatment and analysis of degenerative diseases (Yamanaka, 2007).”